S.SanchezJ
According to 3 multicenter, randomized, double-blind, placebo-controlled obesity trials (BMI 30, or BMI 27 with at least 1 comorbidity of hypertension, dyslipidemia, or type 2 diabetes) conducted to evaluate the effect of CONTRAVE in conjunction with reduced caloric intake and increased physical activity, the average percentage of weight loss in patients at 56 weeks ranged from 3.7% to 8.1% with CONTRAVE, compared to 1.3% to 4.9% with placebo
Your doctor's assessment, your diagnosed conditions, and your specific plan details are critical
European survey finds over three-quarters of adults with obesity have attempted to lose weight in the past year, but most have been unsuccessful
doi: 10.1161/CIRCULATIONAHA.107.744490 123 KatsuumiGShimizuIYoshidaYMinaminoT
Clinical Update 11/20/2024 Saffron Top Picks Unfortunately, our original Top Picks among saffron supplements have been discontinued